- Home
- CELH vs INCY Comparison
CELH vs INCY Comparison
Compare CELH & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- INCY
- Stock Information
- Founded
- CELH 2004
- INCY 1991
- Country
- CELH United States
- INCY United States
- Employees
- CELH N/A
- INCY N/A
- Industry
- CELH Beverages (Production/Distribution)
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CELH Consumer Staples
- INCY Health Care
- Exchange
- CELH Nasdaq
- INCY Nasdaq
- Market Cap
- CELH 16.6B
- INCY 17.0B
- IPO Year
- CELH N/A
- INCY 1993
- Fundamental
- Price
- CELH $61.78
- INCY $88.09
- Analyst Decision
- CELH Strong Buy
- INCY Buy
- Analyst Count
- CELH 18
- INCY 19
- Target Price
- CELH $62.61
- INCY $81.73
- AVG Volume (30 Days)
- CELH 4.6M
- INCY 1.6M
- Earning Date
- CELH 11-05-2025
- INCY 10-28-2025
- Dividend Yield
- CELH N/A
- INCY N/A
- EPS Growth
- CELH N/A
- INCY 900.04
- EPS
- CELH 0.39
- INCY 4.37
- Revenue
- CELH $1,666,480,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- CELH $84.05
- INCY $16.41
- Revenue Next Year
- CELH $29.58
- INCY $10.86
- P/E Ratio
- CELH $156.07
- INCY $20.15
- Revenue Growth
- CELH 11.85
- INCY 18.87
- 52 Week Low
- CELH $21.10
- INCY $53.56
- 52 Week High
- CELH $66.74
- INCY $92.86
- Technical
- Relative Strength Index (RSI)
- CELH 55.86
- INCY 59.22
- Support Level
- CELH $59.73
- INCY $84.38
- Resistance Level
- CELH $66.00
- INCY $92.86
- Average True Range (ATR)
- CELH 2.46
- INCY 2.41
- MACD
- CELH 0.10
- INCY 0.07
- Stochastic Oscillator
- CELH 39.59
- INCY 52.46
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.